Madison Keats Facilitates Licensing of Wound Healing Technology to Smith & Nephew.

March 19, 2003, Charlotte, NC. Madison Keats announced today the investment bank has facilitated the licensing of Encelles E-Matrix wound healing technology to Smith & Nephew.

Contact: David Teifer, Managing Director Madison Keats (PRWEB) March 21, 2003 -4121 ext. 1018

March 19, 2003, Charlotte, NC. Madison Keats announced today the investment bank has facilitated the licensing of Encelles E-Matrix wound healing technology to Smith & Nephew. E-Matrix is a tissue regeneration product currently being clinically tested for the treatment of diabetic foot ulcers. Smith & Nephew has agreed to fund the first phase of clinical development of the diabetic foot ulcer application. Encelles chief executive officer, Jim Woodward stated, Encelle is excited about this collaboration with the world leader in advanced wound management." Encelle also raised $4 million in equity financing from inside investors in conjunction with this transaction.

About Encelle:
Encelle is a life science company developing novel products for regenerative medicine. The Company has developed and patented a platform tissue regeneration technology that is expected to have broad application for multiple therapeutic indications. The initial embodiment of this technology is in an injectable biopolymer that has been shown to regenerate normal tissue in serious skin wounds.

About Madison Keats:
Madison Keats is a life science investment bank. The firm provides advisory services and focuses on orchestrating technology licensing, creative financing, and mergers and acquisitions. Madison Keats works exclusively within the life sciences industry. Headquartered in Charlotte, North Carolina, the firm is strategically situated in the second largest banking center in the U.S. and within close proximity to Research Triangle Park in North Carolina. For additional information, please visit www.madisonkeats.com.